Evidence map›Paper›PMID 32325026›Full record

ArticleLancet (London, England)2020

Endothelial cell infection and endotheliitis in COVID-19.

Zsuzsanna Varga, Andreas J Flammer, Peter Steiger, Martina Haberecker, Rea Andermatt, Annelies S Zinkernagel, Mandeep R Mehra, Reto A Schuepbach, Frank Ruschitzka, Holger Moch

9 registry-linked trialsAbstract readCase ReportsLetter
In one paragraph

Article in Lancet (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 9 registered trials, which are not on this map. Cited by 3,778 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3,778citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04390555 unknown statusnot on this map

COVID-19 in Hospitalised Patients With Preexisting CArdioVascular Diseases and/or Cardiac Involvement and/or Cardiovascular Risk Factors: the Global PCHF-COVICAV Registry

Typeobservational_patient_registrySponsorUniversity of ZurichRan2020 to 2021Enrolled1,500ConditionsCOVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor, Heart Failure
NCT04516941 phase3terminatednot on this mapstarted 2021, after this paper: background citation

Efficacy and Safety of Edoxaban and or Colchicine for Patients With SARS-CoV-2 Infection Managed in the Out of Hospital Setting

TypeinterventionalSponsorInsel Gruppe AG, University Hospital BernRan2021 to 2022Enrolled60ConditionsSARS-CoV Infection, COVID-19ArmsEdoxaban Tablets, Colchicine Tablets
NCT04771000 phase2terminatednot on this mapstarted 2021, after this paper: background citation

A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19

TypeinterventionalSponsorNoorik Biopharmaceuticals AGRan2021 to 2023Enrolled88ConditionsCovid19, HypoxemiaArmsAmbrisentan, Placebo
NCT04808895 phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2021 to 2021Enrolled204ConditionsCOVID-19, Thrombosis PulmonaryArmsAcetylsalicylic acid, Placebo
NCT04853953 unknown statusnot on this mapstarted 2021, after this paper: background citation

Incidence of Bleeding Complications in Critically Ill COVID-19 Patients With Acute Respiratory Distress Syndrome on Veno-venous ECMO

TypeobservationalSponsorUniversity of ZurichRan2021 to 2021Enrolled400ConditionsAcute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation Complication, Corona Virus InfectionArmsIncidence of bleeding complications in ARDS patients on veno-venous ECMO
NCT04881214 naunknown statusnot on this map

Impact of COVID-19 Pneumonia on Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program (COVISQAR)

TypeinterventionalSponsorUniversity Hospital, GenevaRan2020 to 2023Enrolled60ConditionsCovid19 Pneumonia, Chronic Thromboembolic Pulmonary Hypertension, Myopathy, Restrictive Lung DiseaseArmsPulmonary rehabilitation
NCT05286268 unknown statusnot on this mapstarted 2022, after this paper: background citation

The Role of Ischemia Modified Albumin in Patients With COVID-19

TypeobservationalSponsorLarissa University HospitalRan2022 to 2022Enrolled194ConditionsCOVID-19ArmsIschemia Modified Albumin
NCT07312409 recruitingnot on this mapstarted 2026, after this paper: background citation

Does Taurine Supplementation Improve Vascular Function and Orthostatic Responses in Long COVID?

Typeobservational_patient_registrySponsorYork UniversityRan2026 to 2027Enrolled30ConditionsLong COVID SyndromeArmsTaurine supplementation
NCT07559994 naactive not recruitingnot on this mapstarted 2021, after this paper: background citation

Diagnostic and Clinical Management of Non-Obstructive Myocardial Ischemia in Patients With Long Covid-19 Syndrome and New Onset Chest Pain: the Long Covid-19 INOCA Trial

TypeinterventionalSponsorFundacion Investigacion Interhospitalaria CardiovascularRan2021 to 2026Enrolled108ConditionsAngina (Stable), INOCA (Ischemia With Non Obstructive Coronary Artery Disease), Long COVID-19 SyndromeArmsCoronary functional test
3 · Its place in the literature

Who cites it

3,778 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

3,718 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Zsuzsanna VargaDepartment of Pathology and Molecular Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Andreas J FlammerDepartment of Cardiology, University Heart Center, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Peter SteigerInstitute for Intensive Care Medicine, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Martina HabereckerDepartment of Pathology and Molecular Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Rea AndermattInstitute for Intensive Care Medicine, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Annelies S ZinkernagelDivision of Infectious Diseases, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Mandeep R MehraDepartment of Internal Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Reto A SchuepbachInstitute for Intensive Care Medicine, University Hospital Zurich, CH-8091 Zurich, Switzerland.
Frank RuschitzkaDepartment of Cardiology, University Heart Center, University Hospital Zurich, CH-8091 Zurich, Switzerland. Electronic address: frank.ruschitzka@usz.ch.
Holger MochDepartment of Pathology and Molecular Pathology, University Hospital Zurich, CH-8091 Zurich, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Coronavirus InfectionsPandemicsPneumonia, ViralAgedAutopsyBetacoronavirusCOVID-19Endothelial CellsFemaleHumansInflammationKidneyKidney TransplantationLiverLungMale

Identifiers

PMID32325026
PMCPMC7172722

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

and 3 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.